Becton Dickinson & Co (BDX) Stock Price & Analysis
Becton Dickinson & Co (BDX) rose 2.08% to USD 152.04 as of June 9, 2026 at 22:39 UTC, according to Nexqual real-time market data.
BDX last closed at USD 148.94; the session ranged USD 148.7–152.55 on volume of 2,214,855 shares. Market capitalization is $41.89B, with a 52-week range of USD 127.59–187.35 (NYQ). Source: Nexqual, June 9, 2026 at 22:39 UTC.
Key Statistics (as of June 9, 2026 at 22:39 UTC)
| Price | USD 152.04 |
|---|---|
| Change | ▲ 2.08% (up) |
| Previous Close | USD 148.94 |
| Open | USD 149.72 |
| Day Range | USD 148.7 – 152.55 |
| 52-Week Range | USD 127.59 – 187.35 |
| Volume | 2,214,855 shares |
| Market Cap | $41.89B |
| Exchange | NYQ |
Technical Analysis (BDX)
Nexqual's technical model rates BDX "NEUTRAL" based on 4 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 22:39 UTC.
| Overall Signal | NEUTRAL |
|---|---|
| RSI (14) | 55.2 (neutral) |
| vs SMA50 | Above (USD 150.41) |
| MACD | -0.03 (negative) |
Analyst Ratings (BDX)
Wall Street analysts rate BDX "Buy" based on 13 analysts, with a mean price target of USD 181.23 (range USD 150–225), per Nexqual as of June 9, 2026 at 22:39 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 181.23 |
| High Target | USD 225 |
| Low Target | USD 150 |
| Buy / Hold / Sell | 6 / 9 / 0 |
Earnings (BDX)
| Next Earnings Date | 2026-08-06 |
|---|---|
| EPS Estimate | USD 3.13 |
| Revenue Estimate | $4.89B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 2.9 vs est 2.77 ▲ beat |
| 2025-12-31 | USD 2.91 vs est 2.8 ▲ beat |
| 2025-09-30 | USD 3.96 vs est 3.91 ▲ beat |
| 2025-06-30 | USD 3.68 vs est 3.4 ▲ beat |
Source: Nexqual, June 9, 2026 at 22:39 UTC.
Financials & Fundamentals (BDX)
| Total Revenue | $22.23B |
|---|---|
| Revenue Growth (YoY) | +5.20% |
| Gross Margin | +47.09% |
| Operating Margin | +14.74% |
| Profit Margin | +5.12% |
| ROE | +6.67% |
| Debt / Equity | 71.6 |
| Current Ratio | 0.94 |
| Total Cash | $816.00M |
| Total Debt | $17.28B |
| Free Cash Flow | $4.53B |
Source: Nexqual, June 9, 2026 at 22:39 UTC.
Financial Health Score (BDX)
Nexqual rates Becton Dickinson & Co's overall financial health "Solid" across five dimensions, as of June 9, 2026 at 22:39 UTC.
| Growth | Solid — Revenue +8% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 47%, operating 15% |
| Balance Sheet | Mixed — $816M cash vs $17.3B debt |
| Cash Flow | Strong — FCF $4.53B, 21% margin |
| Efficiency | Mixed — ROE 7%, ROA 4.4% |
Ownership (BDX)
| Insider Ownership | +0.41% |
|---|---|
| Institutional Ownership | +99.29% |
| Shares Outstanding | 275.54M |
| Float | 274.74M |
| Short % of Float | +3.48% |
Source: Nexqual, June 9, 2026 at 22:39 UTC.
Leadership (BDX)
Becton Dickinson & Co is led by Thomas E. Polen (age 52), President, CEO & Chairman, per Nexqual as of June 9, 2026 at 22:39 UTC.
| President, CEO & Chairman | Thomas E. Polen (age 52) |
|---|---|
| Executive VP & President of Medical Segment and BioPharma Systems Segments | Michael Garrison (age 56) |
| Executive VP & Chief Revenue Officer | Michael C. Feld (age 44) |
| Executive VP & CFO | Vitor Roque (age 42) |
| Executive VP & CTO | Elizabeth McCombs (age 48) |
Major Backers & Investors (BDX)
Notable institutional backers of Becton Dickinson & Co include First Eagle Investment Management, LLC, T. Rowe Price, Invesco, according to Nexqual as of June 9, 2026 at 22:39 UTC.
Active Investors
| Investor | Stake |
|---|---|
| First Eagle Investment Management, LLC | 7.25% |
| T. Rowe Price | 5.62% |
| Invesco | 3.69% |
| Massachusetts Financial Services Co. | 3.3% |
| Wellington Management | 2.4% |
| Fidelity | 1.32% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Vanguard Group | 21.49% |
| BlackRock | 10.83% |
| State Street | 6.25% |
| Geode Capital | 2.58% |
Source: Nexqual, June 9, 2026 at 22:39 UTC.
From Becton Dickinson & Co's Latest SEC 10-K Filing (filed 2025-11-25)
Key Strengths & Strategy (as disclosed to the SEC)
- Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
- It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments.
- It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products.
- The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BAX | Baxter International Inc. | USD 20.03 | ▲ 3.35% |
| APD | Air Products and Chemicals, Inc | USD 282.98 | ▲ 0.22% |
| CAH | Cardinal Health, Inc. | USD 212.67 | ▲ 3.38% |
| DOV | Dover Corporation | USD 220.97 | ▲ 2.89% |
| ITW | Illinois Tool Works Inc. | USD 256.55 | ▲ 1.52% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 22:39 UTC. This page is informational and not investment advice.